Showing 1 to 9 of 9 results
Congress Proposes Safe Beauty Bills to Ban Toxic Chemicals in Hair Products
The U.S. Congress introduced four bills to ban or regulate dangerous chemicals in hair products, primarily targeting those used by Black women, based on studies linking ingredients to cancer and other health problems, and following a 2022 law that gave the FDA authority but little change.
Congress Proposes Safe Beauty Bills to Ban Toxic Chemicals in Hair Products
The U.S. Congress introduced four bills to ban or regulate dangerous chemicals in hair products, primarily targeting those used by Black women, based on studies linking ingredients to cancer and other health problems, and following a 2022 law that gave the FDA authority but little change.
Progress
36% Bias Score
Lasik Surgery Complications Linked to Multiple Suicides
The suicide of Pennsylvania police officer Ryan Kingerski, following debilitating complications from Lasik eye surgery, has brought to light numerous similar cases resulting in severe suffering and suicide, prompting concerns about the procedure's actual safety and marketing practices.
Lasik Surgery Complications Linked to Multiple Suicides
The suicide of Pennsylvania police officer Ryan Kingerski, following debilitating complications from Lasik eye surgery, has brought to light numerous similar cases resulting in severe suffering and suicide, prompting concerns about the procedure's actual safety and marketing practices.
Progress
72% Bias Score
Kennedy Demands Removal of Artificial Food Dyes, Threatening Food Companies
Robert F. Kennedy Jr. ordered major food companies like Kraft Heinz and General Mills to remove artificial dyes from products by the end of his term, threatening unspecified government action; this led to significant stock drops and is part of his "Make America Healthy Again" initiative to increase ...
Kennedy Demands Removal of Artificial Food Dyes, Threatening Food Companies
Robert F. Kennedy Jr. ordered major food companies like Kraft Heinz and General Mills to remove artificial dyes from products by the end of his term, threatening unspecified government action; this led to significant stock drops and is part of his "Make America Healthy Again" initiative to increase ...
Progress
56% Bias Score
Trump's Pharmaceutical Tariffs: A Risky Gamble
President Trump's proposed reciprocal tariffs on pharmaceuticals, potentially effective April 2, aim to boost domestic manufacturing but risk higher drug prices and shortages in the U.S. due to increased costs and skepticism from major overseas manufacturers.
Trump's Pharmaceutical Tariffs: A Risky Gamble
President Trump's proposed reciprocal tariffs on pharmaceuticals, potentially effective April 2, aim to boost domestic manufacturing but risk higher drug prices and shortages in the U.S. due to increased costs and skepticism from major overseas manufacturers.
Progress
52% Bias Score
Harvard Doctor Issues Warning: Fragrances Linked to Cancer and Infertility
Harvard professor Dr. Trisha Pasricha warns against using perfumes and colognes due to evidence linking phthalates, endocrine-disrupting chemicals found in many scented products, to cancer, infertility, and other health problems; the FDA lacks sufficient data on their safety, while stricter regulati...
Harvard Doctor Issues Warning: Fragrances Linked to Cancer and Infertility
Harvard professor Dr. Trisha Pasricha warns against using perfumes and colognes due to evidence linking phthalates, endocrine-disrupting chemicals found in many scented products, to cancer, infertility, and other health problems; the FDA lacks sufficient data on their safety, while stricter regulati...
Progress
64% Bias Score
US GLP-1 Drug Affordability Crisis
High costs and limited insurance coverage of GLP-1 weight-loss drugs like Ozempic and Wegovy are creating an affordability crisis in the US, with millions losing coverage in 2025; potential solutions include allowing compounding pharmacies to produce personalized prescriptions and revoking patent ex...
US GLP-1 Drug Affordability Crisis
High costs and limited insurance coverage of GLP-1 weight-loss drugs like Ozempic and Wegovy are creating an affordability crisis in the US, with millions losing coverage in 2025; potential solutions include allowing compounding pharmacies to produce personalized prescriptions and revoking patent ex...
Progress
52% Bias Score
HHS Budget Cuts Threaten Public Health
The Department of Health and Human Services (HHS) announced drastic budget cuts totaling $40 billion, resulting in approximately 20,000 job losses across numerous agencies, impacting public health programs, research, and disease surveillance, with potentially severe consequences.
HHS Budget Cuts Threaten Public Health
The Department of Health and Human Services (HHS) announced drastic budget cuts totaling $40 billion, resulting in approximately 20,000 job losses across numerous agencies, impacting public health programs, research, and disease surveillance, with potentially severe consequences.
Progress
60% Bias Score
L'Oréal Recalls Face Cream Due to Benzene Contamination
L'Oréal issued an urgent recall of its La Roche-Posay Effaclar Duo face cream in the US due to potential benzene contamination, a known carcinogen, following discussions with the FDA; the UK is unaffected.
L'Oréal Recalls Face Cream Due to Benzene Contamination
L'Oréal issued an urgent recall of its La Roche-Posay Effaclar Duo face cream in the US due to potential benzene contamination, a known carcinogen, following discussions with the FDA; the UK is unaffected.
Progress
40% Bias Score
Lilly Intervenes in Lawsuit over Compounded Tirzepatide Drugs
Eli Lilly joined a lawsuit against the FDA, contesting the agency's October 2023 decision ending the shortage designation for its tirzepatide-based drugs (Zepbound and Mounjaro), impacting the legality of cheaper compounded alternatives. The FDA affirmed its decision in December, but the compounding...
Lilly Intervenes in Lawsuit over Compounded Tirzepatide Drugs
Eli Lilly joined a lawsuit against the FDA, contesting the agency's October 2023 decision ending the shortage designation for its tirzepatide-based drugs (Zepbound and Mounjaro), impacting the legality of cheaper compounded alternatives. The FDA affirmed its decision in December, but the compounding...
Progress
36% Bias Score
Showing 1 to 9 of 9 results